Other
https://doi.org/10.20471/may.2020.57.01.09
Ansofaxine Hydrochloride
Vjekoslav Peitl
orcid.org/0000-0003-4163-6411
; Department of Psychiatry UHC Sestre milosrdnice, Zagreb, Croatia
Darko Vlahović
orcid.org/0000-0002-4693-3450
; Department of Psychiatry UHC Sestre milosrdnice, Zagreb, Croatia
Abstract
Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor that inhibits serotonin, dopamine and norepinephrine reuptake. This novel triple reuptake inhibitor is a carboxylic acid ester prodrug of desvenlafaxine. It is currently under development for the treatment of major depressive disorder - a frequent and heterogeneous disorder induced by a complex pattern of genetic, epigenetic, developmental, and environmental factors.
Keywords
Hrčak ID:
245985
URI
Publication date:
20.11.2020.
Visits: 2.462 *